Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2011 Jan 7;17(6):790–799. doi: 10.1016/j.bbmt.2010.12.712

Figure 5. ECP-treated splenocytes prevent GVHD-associated weight loss when used prior to alloreactive T cell infusion, and preserve responses to a male DC vaccine.

Figure 5

A. F1 mice were given TCD B6 bone marrow (BM) on day +0 followed by B6 DLI on days +14 and +28 to induce GVHD. ECP treatment was given as a separate injection just prior to DLI infusion as GVHD prophylaxis, and all groups were followed for weight loss, 8 mice/group, * = p < 0.05, ** = p < 0.01. B. ELISPOT was performed on day +42 to quantitate IFN-γ production from UTY, SMCY and DBY-reactive T cells, 6–8 mice/group, ** = p < 0.01, *** = p < 0.001.